Does a biosimilar label copy the reference product's label, and can it copy wrong words?

Largely, yes. The FDA's draft guidance recommends that biosimilar labeling incorporate relevant data and information from the reference product's labeling, with appropriate modifications. Carrying text across is a copy job, and a faithful copy carries a correctly spelled wrong word with it, so the biosimilar's own read for meaning matters.

This page is general information, not legal or regulatory advice.

What the FDA recommends

The FDA's guidance Labeling for Biosimilar and Interchangeable Biosimilar Products is a draft from September 2023. As of October 2026, the FDA lists it as a draft, not for implementation. It says its recommendations apply to the Prescribing Information, with some recommendations on FDA-approved patient labeling.

The draft recommends incorporating relevant data and information from the reference product labeling, with appropriate modifications. It also recommends a biosimilarity statement in the Highlights, on the line immediately beneath the initial U.S. approval, saying the product is biosimilar to the reference product, with a footnote explaining what biosimilar means.

Names: which product a line refers to

The draft says the biosimilar's own name should be used in text specific to it, and in directive statements and recommendations for preventing, monitoring, managing or mitigating risks. When the text describes clinical studies or data from the reference product, the draft says the reference product's proper name should be used. It also describes using the shared core name for statements that apply to the reference product and its biosimilars. A biological product's proper name generally includes a distinguishing suffix of four lowercase letters attached to the core name with a hyphen.

Our view: that means a biosimilar label mixes copied text with deliberate name changes, line by line. Each changed line is new text, and new text needs a read.

Where copied text can go wrong

Made-up example: a copied warning should say "hypotension" but the biosimilar version says "hypertension", while the reference product's text is correct. The copy step added the error, and nobody reading only for the name changes sees it.

Why spellcheck misses it

Both words are real and spelled correctly, so spellcheck passes them. A check focused on whether each name was switched correctly won't look at the rest of the sentence.

What to check next

Practice advice:

• After incorporating reference product text, read the risk, dosing and contraindication lines for meaning, not only for name changes.
• Check the biosimilarity statement and its footnote against the draft guidance's wording.
• Check that each directive or risk statement uses the name the guidance recommends.
• When the reference product's labeling changes, read the carried-over changes for meaning too.

For the same copy problem on generics, see does a generic label have to match the brand.

This is our reading of public guidance, not legal or regulatory advice.

Sources

• FDA: Labeling for Biosimilar and Interchangeable Biosimilar Products (draft guidance, September 2023)
• FDA: Labeling for Biosimilar and Interchangeable Biosimilar Products (draft guidance PDF)

Last reviewed: October 18, 2026

More on contextual errors in FDA DailyMed labels.

Questions about wording on your own labels? Talk to us.

We scan freshly published FDA DailyMed labels every day and pull out these high-stakes wrong words.

Every Tuesday and Friday, a new case like this lands in your inbox if you subscribe.

Does a biosimilar label copy the reference product label?

The FDA's draft guidance recommends incorporating relevant data and information from the reference product labeling, with appropriate modifications.

What is the biosimilarity statement?

A statement in the Highlights, beneath the initial U.S. approval, saying the product is biosimilar to its reference product, with a footnote explaining what biosimilar means.

Is the FDA's biosimilar labeling guidance final?

No. As of October 2026, it's a draft guidance from September 2023.

What goes in a biosimilar's prescribing information?

The draft says relevant data and information from the reference product labeling, with appropriate modifications, plus the biosimilarity statement and the biosimilar's own name where the text is specific to it.

Can a biosimilar label carry a wrong word from the copy step?

Yes. A correctly spelled wrong word can be carried over or introduced while copying, and spellcheck passes it.